semaj83/ctmatch_classification huggingface dataset:
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  HIV Infections Subjects must have Normal history and physical exam Negative ELISA for HIV Normal cell-mediated immune responses using Merieux skin test Normal urinalysis  Co-existing Condition: Subjects with the following conditions are excluded Evidence of psychological or psychiatric problems that may lead to noncompliance with study requirements Positive syphilis serology. If serology is documented as a false positive or is due to a remote (> 6 months) treated infection, subject is eligible Circulating hepatitis B surface antigen. Subjects with the following prior conditions are excluded History of immunodeficiency, chronic illness, autoimmune disease, or use of immunosuppressive medications History of anaphylaxis or other adverse reactions to vaccines. Prior Medication: Excluded Prior HIV vaccines Immunoglobulins or vaccines within the past 3 months Experimental agents within the past 30 days. Prior Treatment: Excluded Blood transfusions or cryoprecipitates within the past 3 months. Identifiable high-risk behavior for HIV infection, including
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  HIV Infections Pregnancy A woman may be eligible for this study if She is HIV-positive She is at least 34 weeks pregnant She has a history of at least 4 weeks of continuous oral ZDV during her current pregnancy and tolerated it well She has given consent for her newborn to participate in this study. (The father must also give consent if he is available after reasonable attempts to contact him. A woman under 18 needs the consent of a parent or legal guardian for her and her infant to participate.)  A woman will not be eligible for this study if She is taking part in another study of HIV treatment during pregnancy Her infant has a life-threatening illness indicated in an ultrasound Her infant does not appear to be growing normally in the womb She has a cesarean section She has abnormal blood test results She has severe nausea, vomiting, or other problems of the stomach and intestines at the time of study entry She has an active opportunistic (AIDS-related) infection or other serious infection at the time of study entry The study staff cannot find a usable vein The study doctor feels that she cannot take drugs by mouth
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 13.0-999.0,  HIV Infections HIV Wasting Syndrome Patients must have HIV infection Stable weight CD4+ cell count <200 cells/mm3 Life expectancy of at least 6 months Parent or legal guardian to sign written, informed consent for patients < 18 years old  Co-existing Condition: Patients with any of the following symptoms or conditions are excluded Active opportunistic infection, requiring acute treatment Malignancy (other than stable cutaneous Kaposi's sarcoma that does not require systemic chemotherapy) Diabetes mellitus or other conditions requiring special dietary restrictions Body mass index (BMI) >= 29.0 kg/m2 Disorders or conditions that, in the treating clinician's opinion, may prevent adequate compliance with protocol requirements. Concurrent Medication: Excluded Growth hormone Megestrol acetate (Megace) Cyproheptadine (Periactin) Dronabinol (Marinol)
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  HIV Infections Patients may be eligible for the main study if they Became infected with HIV within the last 120 days Are at least age 16 and have written consent of a parent or guardian if under 18 Are willing to practice abstinence or use barrier methods of birth control, such as condoms Are available for at least 72 weeks Patients may be eligible for 1 of the 2 substudies if they Are at least age 16 and have written consent of a parent or guardian if under 18 Have had HIV infection for more than 1 year and have a CD4 cell count greater than 500 cells/mm3, or do not have HIV infection but are at risk of getting HIV because of their lifestyle, such as sexual activity or injection drug use Have never had hepatitis B infection or a hepatitis B vaccine and they are available for 28 weeks (hepatitis B vaccine substudy only) Have not received a tetanus shot in the past 5 years, have never had an allergic reaction to a tetanus shot, and are available for 8 weeks (tetanus shot substudy only)  Patients will not be eligible for the main study if they Have taken anti-HIV drugs for more than 7 days for the treatment of HIV. However, anti-HIV drugs taken to help prevent HIV are acceptable Have certain types of cancer Are receiving an experimental treatment Are pregnant or breast-feeding Are allergic to study drugs Have taken certain medications that may interfere with the study Patients will not be eligible for 1 of the 2 substudies if they Are receiving an experimental treatment Are pregnant or breast-feeding
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 1.5-18.0,  Influenza Your child may be eligible for this study if he/she Is between the ages of 18 months and 18 years, with consent of parent or guardian Is a resident of the Temple-Belton, Texas area  Your child will not be eligible for this study if he/she Has had a fever within 3 days before vaccination Has symptoms of a weakened immune system Has had a wheezing episode within the past 2 weeks Has moderate to severe asthma Is allergic to eggs Needs to take aspirin on a regular basis Has received another vaccine or study drug in the past month
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 8.0-99.0,  Pulmonary Disease Patients 8 years old and older with signs or symptoms of pulmonary disease of medical interest to the professional staff of CPB will be eligible for participation in this protocol. Only standard diagnostic procedures and conventional therapy will be performed. Patients will not be subjected to any research procedures. This protocol does not commit the NIH to medical or surgical treatment of protocol participants after discharge. Patients will be discharged to the referring physician. Consenting to pregnancy testing in minors of childbearing age: We will inform the minor during the assent process that for safety, we need to do a pregnancy test. She will also be told that if it is positive, we will counsel her and help her tell her parents. If the minor does not want to proceed she will be advised not to sign assent and her enrollment on this training protocol will end  Patients without symptoms of pulmonary disease will be excluded from this protocol
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.25-16.0,  HIV Infections Your child may be eligible for this study if he/she Is 3 months to 16 years old Is HIV-positive Has never taken protease inhibitors or has previously taken ritonavir (RTV), saquinavir (SQV), or indinavir (IDV) and is willing to stop the medication at study entry Is taking an anti-HIV drug combination that will not change during at least the 2 weeks prior to study entry Agrees to use effective barrier methods of birth control, such as condoms, during the study Has consent of parent or guardian  Your child will not be eligible for this study if he/she Has ever taken NFV Has a history of opportunistic (AIDS-related) infection Has any disease or illness that would prevent him/her from completing the study, including cancer Has taken certain medications, including protease inhibitors at study entry Is receiving an HIV vaccine at study entry Is pregnant
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bladder Cancer Histologically confirmed stage 0 and I (Ta, T1 or Tis) resected transitional cell carcinoma of the bladder No advanced disease or muscle invasion No history of transitional cell carcinoma of the prostate Age: 18 and over Performance status: Not specified Life expectancy: Greater than 3 years Hematopoietic: WBC at least 3500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) Alkaline phosphatase no greater than 3 times ULN SGOT no greater than 3 times ULN Renal: Creatinine no greater than 1.5 times ULN Other: Not pregnant or nursing Fertile patients must use effective contraception At least 5 years since prior malignancy except nonmetastatic squamous cell or basal cell carcinoma of the skin No history of drug interactions which could affect therapy No immunodeficiency PRIOR Biologic therapy: Prior intravesical BCG required (if T1 or Tis pathology and negative cytology PAB) Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to the pelvis Surgery: Not specified Other: Intravesical therapy within 30 days allowed At least 30 days since greater than 2 multivitamins daily
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 13.0-999.0,  HIV Infections Patients may be eligible for this study if they Are HIV-positive Are receiving an anti-HIV drug combination that contains three drugs from at least two classes of anti-HIV drugs (such as protease inhibitors). Patients must have been receiving this drug combination for at least 6 months before study entry. Before beginning this drug combination, patients must have taken either no anti-HIV drugs or only one or two nucleoside analogues (NRTIs) Had a viral load between 5,000 and 100,000 copies/ml before beginning their current anti-HIV therapy Have a viral load below 50 copies/ml while on their current anti-HIV therapy within 2 weeks before study entry Have a CD4 count greater than 350 cells/mm3 at the time of study entry Are at least 13 years old (consent of parent or guardian required if under 18)
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Menopause Postmenopausal Non-smoker BMI <30 Healthy Without surgically-induced menopause Not on HRT or >1 year post HRT Normal mammogram within last year No cardiovascular disease other than mild hypertension
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Active Immunity Healthy Stem Cell Transplantation Male or female subjects who are at least 18 years of age, but no older than 60 years of age. Received complete hepatitis B and/or tetanus/diphtheria vaccination series. If female, have a negative urine or serum pregnancy test within two weeks prior to entry into this study, and agree to avoid pregnancy during entire participation through the use of effective birth control or abstinence. Volunteers reporting good general health and denying any illness that can adversely affect an immune response to a vaccine. No history of a serious adverse event associated with any previous vaccination. Not participating in another experimental vaccine study. Serum hemoglobin greater than or equal to 11 g/dL. No history of hepatitis B. Must not have received a tetanus/diphtheria or hepatitis B booster in the last 6 months. HSCT Male or female subjects who are at least 5 years of age, but no older than 60 years of age. Be enrolled in a HSCT protocol at NIH. Be greater than or equal to 3 months post-HSCT. Received tetanus/diphtheria vaccination series. If female, have a negative urine or serum pregnancy test within two weeks prior to entry into this study, and agree to avoid pregnancy during entire participation through the use of effective birth control or abstinence. No history of a serious adverse event associated with any previous vaccination. Not participating in another experimental vaccine study. Serum hemoglobin greater than or equal to 9 g/dL. No history of hepatitis B. Not receiving any more than replacement glucocorticoid therapy. Not receiving any dose of cyclosporine. No acute graft-versus-host disease grade II or higher, at time of consideration for study. No chronic graft-versus-host disease more involved than localized skin lesions and/or liver dysfunction, at time of consideration for study. Must not have received a tetanus/diphtheria or hepatitis B booster in the last 6 months
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Usher Syndrome Retinitis Pigmentosa Congenital Hearing Impairment Any Ashkenazi Jewish individual with combined hearing and visual loss that is or may be any type of Usher syndrome, or a family member of said individual  Any individual who is not an Ashkenazi Jew or does not have combined hearing and visual loss or whose disease has been previously determined not to be Usher syndrome
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Hot Flashes Hot Flushes Histologic documentation of atypical ductal hyperplasia, ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), or invasive adenocarcinoma of the breast stages I-III A. 2. Current daily tamoxifen use. Any planned surgery, adjuvant chemotherapy or radiation must have been completed. 3. History of bothersome hot flushes: ≥ 7 hot flushes/day, sufficiently severe that intervention is desired. Participants must have had bothersome hot flushes for at least one month prior to enrollment. 4. Postmenopausal status: surgical menopause, no menses for ≥ 1 year or postmenopausal FSH levels. 5. No concurrent use of vitamin E, progestins (Megace® or others), clonidine, belladonna derivative or commercially available soy supplement preparations for treatment of hot flushes. Participants must have at least a 4-week washout period prior to day 1 of run-in if any of these have been used. Participants may be taking low doses of vitamin E that are part of a multivitamin. 6. Concurrent use of anti-depressant, such as Paxil® , Prozac®, or Effexor® is allowed if the participant has been on a stable dose for more than a month and the purpose of the medication is for other than control of hot flushes. If SSRI's are used for hot flashes, they must be discontinued for 4 weeks prior to day 1 of run-in. 7. No concurrent systemic hormone replacement therapy or use of vaginal estrogen creams. Use of the estradiol releasing vaginal ring (Estring®) is allowed. 8. No history of soy or milk intolerance 9. CALGB performance status 0-2
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 28.0-999.0,  Smallpox have a history of previous smallpox vaccination greater than 10 years previous to the date of screening and presence of a vaccination scar females must not be pregnant, lactating and must agree to use an effective form of birth control for the 30 days following vaccination or unable to bear children agree to be available for the entire study and agree to comply with all requirements  children 1 year of age or younger in the household or be in close contact smallpox vaccination within ten years known or suspected Human immunodeficient virus (HIV) infection, primary immunodeficiency disorder, leukemia, lymphoma, or current radiation treatment or use of immunosuppressive or anti-neoplastic drugs or have a household member or intimate contact with the conditions listed above renal disease current or past history of eczema or a household member or direct contact who has eczema known allergy or past allergic reactions to latex gloves or to antibiotics which neomycin, streptomycin, chlortetracycline, and polymyxin B known allergy or past allergic reaction to blood products known allergy to cidofovir or sulfa-containing drugs history of allergic phenomena following smallpox vaccination in the past, including urticaria, erythema multiforme, or Stevens-Johnson syndrome transfusion of blood or treatment with any blood product
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Known carrier of a BRCA-1 or BRCA-2 mutation Copy of laboratory report stating results must be available for review OR At risk for carrying a BRCA-1 or BRCA-2 mutation At least 10% risk by Parmigiana probability model Must have at least 1 breast that has never been involved with cancer and has not been irradiated Hormone receptor status Not specified Age and over Sex Female Menopausal status Not specified Performance status
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Diarrhea Be in very good health  Smoker, or have stopped smoking less than one year ago Pregnant History of chronic illnesses, such as: asthma, chronic sinusitis, or chronic seasonal allergies (such as hay fever) Received a vaccination for Shigella or exposure to Shigella bacteria in a research study or through work in a laboratory Positive for HIV, hepatitis B, and hepatitis C by blood test Using anti-diarrheal, anti-constipation, or antacid medications on a regular basis